Zoetis, Inc. Hits New 52-Week Low at $112.97 Amid Market Struggles

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 112.97 on April 29, 2026. This marks a significant decline, with the stock's performance over the past year reflecting a decrease of 36.35%, contrasting sharply with the S&P 500's gain of 28.33% during the same period. Despite this downturn, Zoetis maintains a robust market capitalization of USD 53,244 million and demonstrates high management efficiency, evidenced by a return on equity of 80.42%. The company has shown a strong ability to service its debt, with a low Debt to EBITDA ratio of 1.22 times, indicating financial stability. Zoetis has also reported positive results for the last six consecutive quarters, with operating cash flow reaching a peak of USD 2,929 million. The company’s net sales have grown at an annual rate of 8.16%, showcasing its potential for long-term growth. However, the stock's current valuation appears to be at a discount compared to its peers, reflecting the challenges it faces in both short-term and long-term performance metrics.